Qualigen Therapeutics Inc
QLGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.43M
Close$
$3.25
1.2% upside
Current Fair Value
1.2% upsideUndervalued by 1.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.43 Million |
|---|---|
| Enterprise Value | $-770,311.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.11 |
| Beta | 0.28 |
| Outstanding Shares | 7,704,597 |
Return
| Return on Equity | -104.98% |
|---|---|
| Return on Assets | -96.07% |
| Return on Invested Capital | -68.41% |
Valuation & Multiples
| P/E Ratio | -0.48 |
|---|---|
| PEG | -0.37 |
| Price to Sales | - |
| Price to Book Ratio | 1.61 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.05 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About AIxCrypto Holdings, Inc.
4 employees
CEO: Kevin A. Richardson AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selecti...